Background: Cardiovascular diseases (CVDs), hypertension and diabetes represent one of the major causes of morbidity and mortality worldwide, and area leading cause of disability. Being preventable conditions, early identification is a public health crucial issue. Several Risk Prediction Models (RPMs) have been investigated in recent decades, but no consensus on gold standard tools has been reached. Aim of this study is therefore to compare the effectiveness of available RPMs in terms of early recognition of CVDs, diabetes and hypertension, in order to assess which are the most effective tools in order to program preventive interventions.
Cardiovascular diseases (CVDs), hypertension and diabetes represent a major health concern, throughout the world, from high-to low-income countries, as a silent epidemic responsible for millions of deaths every year.
CVDs, excluding hypertension, have a global prevalence rate of 6.6% and account for 17.6 million deaths a year, becoming the leading cause of death worldwide (1) .
Hypertension alone is the leading preventable cause of premature death worldwide (2) , being responsible for 7.5 million deaths globally.
In 2010, almost one adult in three (31.1%) had hypertension, although there was a significant gap in prevalence rates between high-and low-income countries: 28.5% (27.3%-29.7%) and 31.5% (30.2-32 .9%) respectively worldwide.
Diabetes (both types 1 and 2) has a prevalence rate of 5.4% globally and it is responsible for 1.4 million deaths every year (3) . Besides being a significant cause of mortality worldwide, CVDs, hypertension and diabetes are also a leading cause of disability. They account together for almost 40% of disability-adjusted life years (DALYs): cardiovascular diseases alone are responsible for 32.3% of total DALYs, hypertension for 3.7% and diabetes for 2.4% (4) .
The epidemiology of these three diseases contributes to explaining the substantial economic impact they have on national health services globally: in the United States, cardiovascular disease-related direct costs amount to approximately $444 billion (5) , whereas the costs of diabetes are estimated as$327 billion and hypertension is associated within annual estimated cost of $51 billion (6) , most of which (nearly $48 billion) represents direct medical expenses (7) . In recent decades, hypertension and diabetes have shown an increasing trend in terms of prevalence and mortality rates.It has been estimated that the prevalence of diabetes will continue to grow: 1 in 5 to 1 in 3 adults will be affected by 2050. The same is true for mortality rate trends: in the last fifteen years, diabetes-related deaths increased by 1%, and these data are expected to climb dramatically over the coming decades (8) .
The prevalence of hypertension and the associated mortality rates have increased significantly in both men and women (9) .By 2030, projections estimate an increase in prevalence to 44% (10) . Conversely,CVDs have significantlydecreased in terms of prevalence and mortality rate trends (11) , including in those countries that had seen considerable increases until the beginning of the 21st century (12) .
Cardiovascular diseases, hypertension and diabetes are strongly related to each other: diabetes is associated with an increased risk of CVDs, which is exaggerated by concomitant hypertension. These conditions also share the same pathogenic pathways, at both macroscopic and molecular level: oxidative stress, inflammation and fibrosis, causing microvascular and macrovascular complications of diabetes, which also lead to vascular remodelling and dysfunctions in hypertension (13) . Because of the high prevalence and mortality rates associated with CVDs, hypertension and diabetes, and their related direct and indirect costs, early identification of these three diseases is a crucial issue, in terms of obtaining significant savings in global health outcomes and economic expenditures. A number of prediction models focused on these big three non-communicable diseases (NCDs) are currently available, but there is no consensus as to the gold standard tools to be utilised to enable early identification of people at risk. The aim of this study is to evaluate risk prediction models (RPMs) for CVDs, diabetes and hypertension, in order to assess which are the most effective tools in recognising vulnerable people at an early stage, in particular among high-risk groups (e.g. workers, migrants) and, consequently, to achieve primary and secondary targeted preventive interventions. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 
METHODS
This umbrella systematic review was performed according to a protocol designed a priori, following the PRISMA guidelines (14) . The PubMed, Scopus and Cochrane databases were searched electronically on 19 February 2018, using combinations of the relevant medical subject heading (MeSH) terms, key words, and word variants for "risk prediction scores" and "cardiovascular disease", "diabetes" and "hypertension", as shown in Table 1 . The search and selection criteria were restricted to the following: systematic reviews, with or without meta-analysis, as type of study; general population aged 18-65 with no major illness; the comparison of at least two risk prediction models; English language. For the PubMed database only, further specific filters were added: only articles on humans and with abstracts available. No restrictions were applied in terms of publication date for all three databases. Reference lists of relevant articles and reviews were hand-searched for additional reports.
The study protocol was registered on the PROSPERO (International prospective register of systematic reviews) database (Registration number: CRD42018088012). (risk AND prediction AND model AND (systematic AND review OR meta-analysis)) Medic For each database, two different authors independently screened article titles and abstracts: MM and AA for Scopus, AV and DCM for PubMed/Medline, AV and AA for Cochrane Library. Disagreements were discussed by the authors and resolved by consensus or by recourse to a third author (FL). Every article meeting eligibility criteria -Systematic Reviews/ Meta-Analyses on risk prediction models on CVDs, Diabetes and Hypertension evaluated, by comparison with other RPMs, in adults with no relevant illness-was considered for subsequent qualitative synthesis. Duplicate records were identified and removed, as well as articles including exclusion criteria: any study carried out with the only purpose to develop a new RPM, to validate one, or to propose a diagnostic/prognostic tool, without any comparisons with other prediction models. Studies were henceforth labelled for inclusion or exclusion. The selection process described above is summarised by the PRISMA flow diagram shown in Figure  1 .
Assessment of study quality
Quality assessment of individual studies was performed by applying the AMSTAR tool (15) .According to their score, articles were classified into three groups: low (AMSTAR score <4), medium (AMSTAR score ≥ 4 and ≤ 7), and high quality (AMSTAR score ≥ 8). Four authors (AA, DCM, MM and AV) independently assigned score. Disagreements were resolved by consensus or by discussion with a fifth author (FL) . No reviews were excluded ex-post for quality reasons. Synthesis of the selected reviews was performed according to the guidelines for umbrella review from the Joanna Briggs Institute (16) . A qualitative (narrative) synthesis was performed, comprising the following variables: number of studies included, intervention type, comparison, performance indexes (AUC, C STAT., D-STAT), validation, outcomes (i.e. incidence, prevalence, mortality), quality assessment score.
Risk of bias in individual studies
Risk of bias in individual studies was independently evaluated, using the ROBIS tool (17) , by four authors (AA, DCM, MM and AV). Any disagreements were resolved by consensus or by discussion with a fifth author (FL).
Patient and Public Involvement
As the study design was a systematic review, Patients and Public were not involved. Figure 1 , 3,206 studies were identified through a search of the electronic databases. After title screening, 3,058 studies were excluded because they did not meet the eligibility criteria and nine duplicate articles were removed. Of the 139 studies passing the first evaluation stage, 103 studies were excluded because the topic was not pertinent, sample characteristics were inadequate (i.e. some articles included non-healthy populations), the article type did not meettheinclusion criteria (i.e. some studies were not systematic reviews), or there was no comparison between models. Following reading of the full text of the 36remaining studies, only 12 were deemed relevant for inclusion. 24 studies were excluded because of a lack of comparison model, related but non-pertinent topic or wrong article type. Three additional studies were included after consulting reference lists of relevant articles and reviews293225. An overall number of 15 studies met the eligibility criteria and were included in qualitative synthesis.
RESULTS

As shown in
Quality assessment of the studies
All of the studies were of high-moderate quality, according to the AMSTAR tool, with a mean score of 7.14, (range 5-11): 8 out of 15 (53.4%) were medium quality (AMSTAR ≥ 4 and ≤ 7), and 7out of 15 (46.6%) obtained a score over 8 and were categorised as high quality.
The results of quality assessment have been summarised in graph form, as shown in Figure 2 .
Risk of bias within studies
The results of risk-of-bias evaluation are shown in Table 2 and in Figure 3 . According to the ROBIS tool, only eight articles out of fifteen (53.4%) had a low risk of bias. Two articles had a high risk of bias due to the eligibility criteria: search limitation on English language. Eight articles had a high risk of bias due to the identification and selection process: the most common source of bias was the search limitation to a single database. Nine articles had a high risk of bias due to data collection and study appraisal, in particular because of the lack of formal appraisal tools. Finally, one article had a high risk of bias due to the synthesis and identification process, mainly due to significant heterogeneity of primary sources, and it was subsequently impossible to conduct a meta-analysis. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 
Results of individual studies
The results for all the studies included are summarised qualitatively in Table3. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 Ten studies randomly split the cohort into development and validation cohorts. Eight of these studies split the original cohort equally into development and validation cohorts. Twentyone studies conducted and published an external validation of their risk prediction models within the same article, and eight of these studies used two or more data sets in an attempt to demonstrate the external validity of the risk prediction models.
Table3-Summary of results
internal? Seven risk tools were validated using an external dataset. Fourteen of the tools were validated internally using re-sampling techniques such as bootstrapping and cross-validation. Four of the tools also split their dataset into a "training" set, which was used to create the tool. One risk tool was validated using a partially independent dataset; all cases were used in both the "training" and "test" cohorts however the non-cases were split into these two cohorts.
Prospective cohort study, with a case cohort study random subcohort. Diabetes-morbidity (incidence) General mortality, CVD-mortality and morbidity (incidence), and CHD-mortality and morbidity (incidence) Hypertension morbidity (incidence) CVD mortality, CHD incidence, cerebrovascular disease incidence, CABG or PTCA Diabetes-morbidity (incidence) Diabetes-morbidity (incidence) General mortality, CVD-mortality, and CHD-morbidity (incidence) Hypertension morbidity (incidence) Heart Failure incidence Fatal or non-fatal CHD Fatal or non-fatal: CHD, CVD, myocardial infarction, and stroke Fatal: CHD, CVD, and non-CHD Fatal CVD Fatal or non-fatal stroke Fatal or non-fatal: CHD, myocardial infarction, and stroke; claudication; coronary artery bypass grafting; percutaneous transluminal coronary angioplasty; transient ischaemic attack
Fatal CHD
General mortality, CVD-mortality and morbidity, (incidence), and CHD-mortality and morbidity (incidence) Diabetes-morbidity (incidence and prevalence) CHD, MI/suddenischaemicdeathCHD death, CVD, stroke, CHD, CVD 
Studies on Diabetes
Abbasi et al (18) (AMSTAR 6/11) focused on 16 prospective cohort studies, in order to validate 25 risk-predictive models for type 2 diabetes (T2DM), by means of an external validation cohort. The sample was composed by 38,379 people aged 20-70 with no diabetes at baseline. Incidence of type 2 diabetes was evaluated as outcome. All the studies included reported a C-statistic, ranging from 0.74 to 0.84 for risk at 7.5years, indicating a good discriminatory capability. The risk models had an estimate of calibration, the Hosmer-Lemeshow test, generally indicating good calibration.
Barber et al (19) (AMSTAR 6/11) assessed the applicability of 18 risk assessment tools in individuals with pre-diabetes. Their systematic review included 12 studies, with sample sizes ranging from 1,351 to 7,092. Incidence of pre-diabetes, defined according to American Diabetes Association (ADA) criteria, was considered as primary outcome. Validation (either internal or external) of the risk scores was achieved by evaluating both discrimination and calibration. The internal C-statistic ranged from 0.66 to 0.75. Calibration was stated by Hosmer-Lemeshow goodness-of-fit test value, reported by only two studies and with discordant results. (20) (AMSTAR 6/11) evaluated risk prediction models for type 2 diabetes, including 39 studies comparing 47 different risk tools. The studies had a median sample size of 2,562 people, with an interquartile range from 1,426 to 4,965. No quantitative information was available on discrimination and calibration.
Collins et al
Hu et al (21) (AMSTAR 5/11) evaluated the effectiveness of risk-predictive models for type 2 diabetes in the Asian population. Their systematic review included 43 studies examining 12 riskpredictive models, derived from population samples ranging from 2,677 to 73,961. Discrimination was evaluated by the area under the curve (AUC): this showed a high variability of results, with AUC ranging from 0.66 to 0.91. (22) (AMSTAR 5/11) conducted a systematic review assessing94 risk models for type 2 diabetes. The 43 evaluated perspective cohort studies had a sample size ranging from 399 to 2.54 million people and were focused on incidence of diabetes as primary outcome. Some of the risk models had been externally validated on a different population. The C-statistic index showed high variability, fluctuating between not acceptable (0.60) and good quality (0.91) scores. The same results applied for calibration indicators.
Noble et al
Yoshizawa et al (23) (AMSTAR 8/11) focused on evaluating the predictive ability of a non bloodbased risk prediction model for incidence ofT2DM. The 18 eligible studies included an overall number of 184,011 participants aged 42.4 to 68.4 years. Discrimination, evaluated by the area under the curve, was adequate to good (0.72-0.81).
Studies on CVDs
Cortes-Bergodieri et al (24) (AMSTAR 6/11) assessed the validity of Risk Prediction Models in Latin America and in US people of Hispanic descent. Their review included five cohort studies, comparing the Framingham score with three risk models for CVD and one for Chagas Disease, and investigating incidence and mortality as outcomes. Risk score calibration measured by C-statistic index was good, ranging from 0.69 to 0.80. While they openly admit that the Framingham score needs to be recalibrated for Latin American populations, they also recognise that evidence regarding CVD risk models is "modest at best". Indeed, all the studies included showed a ratio of predicted/observed that was not significant.
Tzoulaki et al (25) (AMSTAR: 5/11) focused on 79 studies on Framingham-based improving models, derived from populations of less than 1,000 to over 10,000 subjects from the USA and the UK. Incidence and mortality for coronary heart disease were measured as outcome. The discrimination ability of the examined scores, evaluated by AUC, was variable from not acceptable to good: the FRS alone model showed an area under the curve between 0.50 and 0.83, whereas FRS with additional predictors ranged from .57 to 0.84. (26) (AMSTAR 6/11) evaluated the ankle-brachial index (ABI) as predictor of cardiovascular events and mortality, compared to the Framingham Risk Score. They included 20 prospective studies concerning general populations from the EU and the US, with sample sizes ranging from 554 to 14,109. The combination of ABI and FRS risk prediction scores had a higher discriminating power compared to FRS alone (0.655 versus 0.646 among men, and 0.658 versus 0.605 among women). Incidence of CVDs was assessed, as primary outcome, using adjusted hazard ratio estimates.
Fowkes et al
The study results showed that ankle-brachial index measurement can be used in addition to FRS in order to improve its predictive power, and the Authors suggested that a combined tool could be useful. (27) (AMSTAR 9/11) performed a comparison of eight risk prediction models for cardiovascular disease. Their review included 20 prospective and retrospective studies, with sample sizes ranging from 403 to 1,072,800. The main outcomes considered were CVD mortality and CVDrelated incidence. Concerning probability for prediction of outcome, there was significant variability among the studies, ranging from poor (0.55) to good (0.85).
Siontis et al
Damen et al (28) (AMSTAR: 7/11) conducted a systematic review examining 212 studies, describing the development of 363 different prediction models for CVD and CHD. Sample size was extremely variable, ranging between 51 and 1,189,845 people, mainly from Europe, Canada and the USA. Measures of predictive performance were reported only in 53% of the studies included, with discriminatory ability from 0.61 to 1.00. In addition, an external validation was performedon136 articles and this most often concerned four models: Framingham, SCORE, QRISK and ATPIII. The median discriminative ability was always acceptable (0.70-0.79), except for the ATPIII score (C statistic index: 0.66). Calibration, estimated as observed: expected ratio, ranged between 0.59 of Framingham-Wilson and 0.94 of QRISK.
Beswick et al (29) (AMSTAR 11/11) included 30 articles evaluating several risk prediction methods for coronary heart disease (CHD) and cardiovascular disease (CVD): 16 studies using convergent validation of Framingham-Anderson based methods and 21 comparisons using different risk scoring methods. The enrolled samples comprised 4,540 to over 205,000 people, aged 5 to 70 years, from US, Australia, Europe and India. Incidence and mortality for coronary heart disease and cardiovascular disease were estimated as primary outcomes.
Only the most recent updates to the Sheffield tables and the Joint British charts showed acceptable sensitivity and specificity compared with the Framingham-Anderson model. In addition, Beswick et al. performed a second systematic review on external validation of Framingham-based risk scoring methods, based on 62 longitudinal or cross-sectional studies conducted on 112 different populations. The articles included reported extreme variability in terms of discriminatory ability, with areas under the curve ranging from not acceptable (0.58) to good (0.85), although with better results in women than in men and in people with more recent baseline examinations. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  p  e  e  r  r  e  v  i  e  w  o  n  l  y Concerning calibration, the predicted:observed ratios ranged from an under-prediction of 0.43 to an over-prediction of 2.87. Generally speaking, under-prediction was greater in people at higher risk, such as subjects with a family history of premature cardiovascular disease, and lower in people at lower risk.
Echouffo-Tcheugui et al (30) (AMSTAR: 6/11) focused on 13 studies evaluating 28 heart failure risk prediction models. They were based on a US and European cohort of 725 to 359,947, aged over 18. Assessed scores had acceptable-to-good discriminatory ability, with C-statistics ranging between 0.71 and 0.87. Calibration, when reported, was generally acceptable. Only two models were externally validated, showing modest-to-acceptable discrimination, with C-statistics from 0.61 to 0.79.
Studies on Hypertension
Sun et al (31) (AMSTAR 9/11) included 26 cohort studies on hypertension assessing 48 risk models, including both traditional risk factors -such as body mass index (BMI), age, smoking, blood pressure (BP) level and parental history of hypertension-with biochemical parameters and genetic factors. Evaluated articles were developed from samples mainly drawn from populations in the US, Eastern Asia and the UK and they included a population aged over 20, with a sample size ranging from 443 to 17.471. All the studies included reported a C-statistic index ranging from 0.74 to 0.79, indicating a good discriminatory capability. Furthermore, most of the studies had an estimate of calibration, by Hosmer-Lemeshow test, that never gave significant results.
Echouffo-Tchegui et al 2013 (32) (AMSTAR 9/11) assessed 11 prospective cohort studies evaluating 15 different risk models for hypertension, with population samples ranging from 1,135 to 11,407 derived from US and Eastern Asian populations. Incidence of hypertension was considered as primary outcome. C-statistic ranged from 0.80 to 0.70, indicating good performance and discrimination. Ten models also estimated calibration, using the Hosmer-Lemeshow test, and this generally reported good calibration.
DISCUSSION AND CONCLUSIONS
Strengths and limitations
To the best of our knowledge, this is the most comprehensive umbrella systematic review on risk prediction models for NCDs, such as diabetes and cardiovascular diseases, with high incidence, prevalence and mortality worldwide. In fact, no other umbrella systematic reviews are available on this issue. The only umbrella systematic review found (33) was focused solely on hypertension. Topics were selected according to these criteria:
1. Epidemiological relevance in terms of incidence and prevalence; 2. The significant link between diabetes, CVD and hypertension in terms of pathogenic pathway and clinical presentation. This is also the reason why cancer was not considered among the inclusion criteria. Many studies had been conducted on NCDs, in particular during the last decade, and the Authors have therefore chosen to use an umbrella methodology for systematic reviews and meta-analyses. Unfortunately, available studies, although apparently being of medium-high quality according to AMSTAR score (mean 7.14 out of 11, ranging from 5 to 11), were based on primary studies of debatable quality, with a large proportion of them lacking discrimination and calibration assessments. Again, publication bias and reporting bias could not be assessed, mostly because of the scarcity of evidence, which may have led to overestimation of effective sizes. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 Likewise, due to the significant heterogeneity of study designs, the risk models involved and the outcomes reported, it was not possible to conduct a meta-analysis. The results were therefore reported narratively.
Summary of evidence
Developing a good predictive score in order to enable early identification of diabetes, hypertension and CVDs is a major public health concern, not just in high-income countries, because of the extremely high incidence and prevalence rates of these diseases and their upward trend worldwide, which results in massive consumption of social, health and economic resources. Despite the amount of evidence on the issue, the average quality of the primary studies included is still poor: no available external validation or model calibration, no standardised study design and optimism bias are just some examples. Furthermore, a number of searches showed that older, and more limited, RPMs had better performance than newer, and more complex, models (27) . The majority of studies, and in particular those predicting diabetes, reported comparisons that were often achieved among scores that were very similar in prediction model tools, such as those differing for a very small number of items (sometimes only one) and focusing on the same population. Probably for this reason, no RPMs on diabetes and hypertension seemed to excel: no significant difference was found in the majority of studies on these two diseases. Conversely, some promising differences among prediction tools were highlighted for CVDs and CHDs. The new RPMs investigated generally used Framingham scores as the main comparison tool. According to Fowkes et al. (26) , the ankle-brachial index, in association with the Framingham tool, improved performance results, albeit only slightly. In addition, QRISK scores provided some evidence of a certain superiority compared to Framingham, in particular in calibration and in discrimination performance (28) . However, it should be pointed out that Framingham-based methods underestimated risk in diabetics, socioeconomically deprived populations, and patients with a strong family history of premature cardiovascular disease (29) . Because of all the limitations described in the available studies and because no clear superiority of one predictive model was identified, it seems legitimate to question whether investing in new risk models is still a good practice, or if it would be a better approach to focus such efforts on external validation of the existing tools.
Conclusions and future perspectives
The wide range of available studies testing risk prediction models on CVDs, CHDs, hypertension and diabetes, which compare almost overlapping tools that often differ only for single entries, does not really contribute to increasing our knowledge of the issue and, rather, merely increases uncertainty. Some more precise evidence is available only for cardiovascular disease prediction: the Framingham score, alone or in combination with the ankle-brachial index, and QRISK score can be confirmed as the gold standard. Further efforts should not be concentrated on creating new scores, but rather on performing external validation of the existing ones. Promising future possibilities on the issue could then involve testing risk scores on wider samples and on certain target populations, with specific exposure risks and for which no robust scientific evidence is currently available, such as workers. These individuals could definitely benefit from early detection of chronic disease, since this is often worsened by occupational exposure and is a cause of disability and absence from work. Benefits could be further improved by supplementing the models with information on lifestyle, personal habits and family history (23) .
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Conclusions: consistent evidence is available only for cardiovascular disease prediction: the Framingham score, alone or in combination with the ankle-brachial index, and the QRISK score can be confirmed as the gold standard. Further efforts should not be concentrated on creating new scores, but rather on performing external validation of the existing ones, in particular on high risk groups. Benefits could be further improved by supplementing existing models with information on lifestyle, personal habits, family and employment history, social network relationships, income and education.
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ARTICLE SUMMARY:
Strengths and Limitations
-This is the most comprehensive umbrella systematic review on RPMs for CVDs, Hypertension and Diabetes to date; -Available studies, although apparently of medium-high quality, were based on primary studies of debatable quality, several of which lack discrimination and calibration assessments; -Grey literature was not searched -Heterogeneity was too high for meta-analysis; results are therefore reported narratively. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 
INTRODUCTION
Cardiovascular diseases (CVDs), hypertension and diabetes represent a major health concern, throughout the world and across income levels, as a silent epidemic responsible for millions of deaths every year.
CVDs, excluding hypertension are the leading cause of death worldwide; they have a global prevalence rate of 6.6% and account for 17.6 million deaths per year (1).
Hypertension alone is the leading preventable cause of premature death worldwide (2), and causes 7.5 million deaths each year (3). In 2010, almost one of every three adults (31.1%) had hypertension, although there was a significant gap in prevalence rates between high-and low-income countries: 28.5% (27.3%-29.7%) and 31.5% (30.2-32.9%) respectively worldwide (2) .
Diabetes (types 1 and 2 combined) has a global prevalence rate of 5.4% and is responsible for 1.4 million deaths every year (3). In addition to being a significant cause of mortality worldwide, CVDs, hypertension and diabetes are also a leading cause of disability. Together they account for almost 40% of disability-adjusted life years (DALYs): cardiovascular diseases alone are responsible for 32.3% of total DALYs, hypertension for 3.7% and diabetes for 2.4% (4).
The epidemiology of these three diseases helps explain the substantial economic impact they have on national health services: in the United States, cardiovascular disease-related direct costs amount to approximately $444 billion per year (5), whereas the costs of diabetes are estimated as $327 billion per year; hypertension has an annual estimated cost of $51 billion (6), most of which (nearly $48 billion) represents direct medical expenses (7) . In recent decades, hypertension and diabetes have shown an increasing trend in both prevalence and mortality rates. It has been estimated that the prevalence of diabetes will continue to grow: 1 in 5 to 1 in 3 adults will be affected by 2050. The same is true for mortality rate trends: in the last fifteen years, diabetes-related deaths increased by 1%, and these data are expected to climb dramatically over the coming decades (8) . The prevalence of hypertension and the associated mortality rates have increased significantly in bothmen and women (9) , and by 2030, prevalence is projected to be 44% (10). Conversely, prevalence and mortality rate trends for CVDs have significantly decreased (11) , including in countries that had seen considerable increases until the beginning of the 21st century (12) .
Cardiovascular diseases, hypertension and diabetes are strongly related to each other: diabetes is associated with an increased risk of CVDs, which is exaggerated by concomitant hypertension. These conditions also share the same pathogenic pathways, at both macroscopic and molecular level: oxidative stress, inflammation and fibrosis, cause microvascular and macrovascular complications in diabetes, and also lead to vascular remodelling and dysfunctions in hypertension (13) . Because of the high prevalence and mortality rates associated with CVDs, hypertension and diabetes, and their related direct and indirect costs, early identification of individuals at high risk for these diseases is crucial; it results in terms of obtaining significant savings in both global health outcomes and economic expenditures. A number of prediction models focused on these three non-communicable diseases (NCDs) is available, but there is no consensus as to the gold standard tools best utilised in practice. The aim of this study is to provide an overview of the currently available risk prediction models (RPMs) for CVDs, Diabetes and Hypertension and to compare their effectiveness at properly recognising vulnerable people, at risk of developing these NCDs. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 
METHODS
This umbrella systematic review was performed following a protocol designed a priori, and reported according to the PRISMA guidelines (14) . The PubMed, Scopus and Cochrane databases were searched electronically on, September 24 th 2019, using combinations of the relevant medical subject heading (MeSH) terms, key words, and word variants for "risk prediction scores" and "cardiovascular disease", "diabetes" and "hypertension", as shown in Table 1 . The search and selection criteria were restricted to the following: systematic reviews, with or without meta-analysis, as the type of study; general population aged 18-65 with no major illness; comparison of at least two risk prediction models; English language. For the PubMed database only two further filters were added: only articles on humans and with abstracts available were included. No restrictions were applied in terms of publication date in any of the databases. Reference lists of relevant articles and reviews were hand-searched for additional reports. The study protocol was registered on the PROSPERO (International prospective register of systematic reviews) database (Registration number: CRD42018088012). Two different authors independently screened the article titles and abstracts in each database: MM and AA for Scopus, AV and DCM for PubMed/Medline, AV and AA for Cochrane Library. Disagreements were discussed by the authors and resolved by consensus or by recourse to a third author (FL). Studies were then labelled for inclusion or exclusion. Every article meeting the eligibility criteria -Systematic Reviews/ Meta-Analyses on risk prediction models on CVDs, Diabetes and Hypertension, evaluated by comparison with other RPMs, in adults with no relevant illness-was considered for subsequent qualitative synthesis; duplicate records were removed, as were articles that included the exclusion criteria: any study carried out with the sole purpose of developing a new RPM, or validating one, or to propose a diagnostic/prognostic tool, without any comparisons to other prediction models. Studies were henceforth labelled for inclusion or exclusion. The selection process described above is summarised by the flow diagram shown in Figure 1 .
Data extraction
Four authors (AA, DCM, MM and AV) extracted the data, including the following variables: number of the included studies; intervention (risk prediction models); comparison; performance: Area Under the receiver-operating characteristic Curve (AUC), C-statistic, D-statistic); validation: internal, external, both or not provided; outcomes: incidence, prevalence, mortality. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 
Assessment of study quality
Quality assessment of individual studies was performed by applying the AMSTAR tool (15) . According to their score, articles were classified into three groups: low (AMSTAR score <4), medium (AMSTAR score ≥ 4 and ≤ 7), and high quality (AMSTAR score ≥ 8).
Four authors (AA, DCM, MM and AV) independently assigned score. Disagreements were resolved by consensus or by discussion with a fifth author (FL). No reviews were excluded ex-post for quality reasons.
A qualitative (narrative) synthesis of the selected reviews was then performed; the guidelines for umbrella review from the Joanna Briggs Institute were applied (16) .
Risk of bias in individual studies
Risk of bias in individual studies was independently evaluated by four authors (AA, DCM, MM and AV), using the ROBIS tool (17) . Any disagreements were resolved by consensus or by discussion with a fifth author (FL).
Patient and Public Involvement
As the study design was a systematic review, neither patients nor the public were involved.
RESULTS
A total of 3612 studies were identified through a search of the electronic databases. After title screening, 3463 studies were excluded because they did not meet the eligibility criteria and nine duplicate articles were removed. Of the 149 studies passing the first evaluation stage, 102 studies were excluded because the topic was not pertinent, sample characteristics were inadequate (i.e. some articles included non-healthy populations), the article type did not meet the inclusion criteria (i.e. some studies were not systematic reviews), or there was no comparison between models. After reading the full text of the 37 remaining studies, 13 were deemed relevant for inclusion. Twentyfour studies were excluded because of a lack of comparison model, related but non-pertinent topic or wrong article type. Three additional studies were included after consulting reference lists of relevant articles and reviews overall, 16 studies met the eligibility criteria and were included in qualitative synthesis.
Quality assessment of the studies
According to the AMSTAR tool, all of the studies were of medium-to-high quality, with a mean score of 7.14, (range 5-11).Specifically, 8 of 15 (53.4%) were of medium quality (AMSTAR ≥ 4 and ≤ 7), and 7 of 15 (46.6%) were of high quality (AMSTAR > 8).
The results of quality assessment have been summarised in graph form (Figure 2 ).
Risk of bias within studies
The results of the risk-of-bias evaluation are shown in Table 2 and Figure 3 . Globally, only nine articles of sixteen (56.25%) had a low risk of bias, according to the ROBIS tool. Two articles had a high risk of bias due to the eligibility criteria: search limitation on English language. Eight articles had a high risk of bias due to the identification and selection process: the most common source of bias was the search limitation to a single database. Nine articles had a high risk of bias due to data collection and study appraisal, in particular because of the lack of formal appraisal tools. Finally, one article had a high risk of bias due to the synthesis and identification 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 F o r p e e r r e v i e w o n l y process, mainly due to significant heterogeneity of primary sources. Given the overall heterogeneity of the retrieved studies, it was impossible to conduct a meta-analysis.
Risk of bias across systematic reviews
We identified all of the ongoing SRs that met our inclusion criteria by searching the PROSPERO database, in order to assess publication bias. Eight ongoing systematic reviews were found, including the present study, and none have been published to date.
Table2 -Risk of bias
Results of individual studies
Overall, 16 studies met the inclusion criteria, 8 of them concerning Diabetes, 6 CVDs and 2 Hypertension.
The results for all the included studies are summarised qualitatively in Table3. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  p  e  e  r  r  e  v  i  e  w  o  n  l  y   8   18  79  26  20  43  12  20  11  13  38  212  5  39  110  12 16
N° of studies included
Non-blood-based risk model for Type Ten studies randomly split the cohort into development and validation cohorts. Eight of these studies split the original cohort equally into development and validation cohorts. Twentyone studies conducted and published an external validation of their risk prediction models within the same article, and eight of these studies used two or more data sets in an attempt to demonstrate the external validity of the risk prediction models.
Prospective cohort study, with a case cohort study random subcohort. Diabetes-morbidity (incidence) General mortality, CVD-mortality and morbidity (incidence), and CHD-mortality and morbidity (incidence) Hypertension morbidity (incidence) CVD mortality, CHD incidence, cerebrovascular disease incidence, CABG or PTCA Diabetes-morbidity (incidence) Diabetes-morbidity (incidence) General mortality, CVD-mortality, and CHD-morbidity (incidence)
Hypertension morbidity (incidence) Heart Failure incidence Fatal or non-fatal MI, Fatal or non-fatal stroke, Fatal, Hard or non-fatal CHD, angina pectoris, TIA, ASCVD Fatal or non-fatal CHD Fatal or non-fatal: CHD, CVD, myocardial infarction, and stroke Fatal: CHD, CVD, and non-CHD Fatal CVD Fatal or non-fatal stroke Fatal or non-fatal: CHD, myocardial infarction, and stroke; claudication; coronary artery bypass grafting; percutaneous transluminal coronary angioplasty; transient ischaemic attack
Fatal CHD
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Studies on CVDs
Cortes-Bergoderi et al (24) (AMSTAR 6/11) assessed the validity of Risk Prediction Models in Latin America and in US people of Hispanic descent. Their review included five cohort studies, comparing the Framingham score with three risk models for CVD and one for Chagas Disease, and investigating incidence and mortality as outcomes. Risk score calibration measured by C-statistic index was good, (0.69 to 0.80). While the Authors openly admit that the Framingham score needs to be recalibrated for Latin American populations, they also recognise that evidence regarding CVD risk models is "modest at best". Indeed, all of the included studies showed a ratio of predicted/observed that was not significant.
Tzoulaki et al (25) (AMSTAR: 5/11) focused on 79 studies on Framingham-based improving models, derived from populations of less than 1,000 to over 10,000 subjects from the USA and the UK. Incidence and mortality for coronary heart disease were measured as outcome.
The discrimination ability of the examined scores, evaluated by AUC, varied from not acceptable to good: the FRS alone model showed an area under the curve between 0.50 and 0.83, whereas FRS with additional predictors ranged from .57 to 0.84.
Fowkes et al (26) (AMSTAR 6/11) evaluated the ankle-brachial index (ABI) as predictor of cardiovascular events and mortality, compared to the Framingham Risk Score. They included 20 prospective studies involving general populations from the EU and the US, with sample sizes that ranged from 554 to 14,109. The combination of ABI and FRS risk prediction scores had a higher discriminating power compared to FRS alone (0.655 versus 0.646 among men, and 0.658 versus 0.605 among women). Incidence of CVDs was assessed, as primary outcome, using adjusted hazard ratio estimates.
The study results showed that ankle-brachial index measurement can be used in addition to FRS to improve its predictive power, and the Authors suggested that a combined tool could be useful.
Siontis et al (27) (AMSTAR 9/11) performed a comparison of eight risk prediction models for cardiovascular disease. Their review included 20 prospective and retrospective studies, with sample sizes ranging from 403 to 1,072,800. The main outcomes considered were CVD mortality and CVD-related incidence. The probability for prediction of outcome varied significantly among the studies, from poor (0.55) to good (0.85).
Damen et al (28) (AMSTAR: 7/11) conducted a systematic review examining 212 studies, that described the development of 363 different prediction models for CVD and CHD. Sample size was extremely variable, ranging between 51 and 1,189,845 people, mainly from Europe, Canada and the USA.
Measures of predictive performance were reported in 53% only of the studies, with discriminatory ability from 0.61 to 1.00. In addition, an external validation test was performed on 136 articles and most often concerned four models: Framingham, SCORE, QRISK and ATPIII. The median discriminative ability was always acceptable (0.70-0.79), except for the ATPIII score (C statistic index: 0.66). Calibration was estimated as observed: expected ratio, ranged from 0.59 of Framingham-Wilson to 0.94 of QRISK.
Beswick et al (29) (AMSTAR 11/11) included 30 articles that evaluated several risk prediction methods for coronary heart disease (CHD) and cardiovascular disease (CVD): 16 studies using convergent validation of Framingham-Anderson based methods and 21 comparisons used different risk scoring methods. The enrolled samples involved 4,540 to over 205,000 people, aged 5 to 70 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 . Results for men and women were compared separately. The authors performed meta-analyses of the included studies, calibration was assessed through the observed vs expected (OE) ratio and discriminative power, through the C-statistic, for 10-year risk predictions. The OE ratio results were very heterogeneous, ranging from 0.58 to 0.79. C-statistic values were highly variable as well (from 0.58 to 0.82). Most of the studies showed overprediction of the expected events, especially in high-risk groups. According to the authors, risk prediction models for CVDs and CHDs showed a similar performance.
Studies on Hypertension
Sun et al (32)(AMSTAR 9/11) included 26 cohort studies on hypertension that assessed 48 risk models and included both traditional risk factors -body mass index (BMI), age, smoking, blood pressure (BP) level and parental history of hypertension-with biochemical parameters and genetic factors. Evaluated articles were based on samples drawn mainly from populations in the US, Eastern Asia and the UK and included a population aged over 20, with a sample size that ranged from 443 to 17.471. All the studies included reported a C-statistic index ranging from 0.74 to 0.79, indicating a good discriminatory capability. Furthermore, calibration estimates of most studies by Hosmer-Lemeshow test showed no significant results.
Echouffo-Tchegui et al 2013 (33) (AMSTAR 9/11) assessed 11 prospective cohort studies that evaluated 15 different risk models for hypertension in population samples from 1,135 to 11,407 subjects from US and Eastern Asian populations. Incidence of hypertension was considered as primary outcome. The C-statistic ranged from 0.80 to 0.70, indicating good performance and discrimination. Ten models also estimated calibration, using the Hosmer-Lemeshow test, and generally reported good calibration. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 
DISCUSSION AND CONCLUSIONS
Summary of evidence
Developing a good predictive score to enable early identification of diabetes, hypertension and CVDs is a major public health concern across countries of all income levels because of the extremely high rates of incidence and prevalence of these diseases, their upward trend worldwide and their massive consumption of social, health and economic resources.
In spite of the amount of evidence on the issue, the average quality of the existing primary studies is poor: they lack external validation, model calibration and standardized study design, and suffer from optimism bias. In fact, a number of searches showed that older and more limited RPMs performed better than newer, more complex models (27) . The majority of studies, in particular those predicting diabetes, reported comparisons that were often achieved with scores that were very similar in prediction model tools, including those differing by a very small number of items (sometimes only one) and those focused on the same population. It is therefore not surprising that no RPMs on diabetes and hypertension have seemed to excel: no significant difference was found in the majority of studies on these two diseases.
Conversely, some promising differences among prediction tools were highlighted for CVDs and CHDs. The new RPMs investigated generally used Framingham scores as the main comparison tool. According to Fowkes et al. (26) , the ankle-brachial index, in association with the Framingham tool, improved performance results, albeit only slightly. In addition, QRISK scores provided some evidence of superiority compared to Framingham, in particular in the areas of calibration and discrimination performance (28) . However, it should be pointed out that Framingham-based methods underestimated risk in diabetics, socioeconomically deprived populations, and in patients with a strong family history of premature cardiovascular disease (29) . Because of the limitations described in the available studies, and because no predictive model was clearly identified as superior, it seems legitimate to question whether investing in new risk models is still a good practice, or if it would be a better approach to focus our efforts on external validation of existing tools.
Strengths and limitations
To the best of our knowledge, this is the most comprehensive umbrella systematic review on risk prediction models for NCDs, such as Diabetes and Cardiovascular Diseases, with high incidence, prevalence and mortality worldwide. In fact, no other umbrella systematic reviews are available on this issue. The only umbrella systematic review found (34) was focused solely on Hypertension. For this review topics were selected according to the following criteria: 1. Epidemiological relevance in terms of incidence and prevalence; 2. The significant link between Diabetes, CVD and Hypertension in terms of pathogenic pathway and clinical presentation. This is also the reason why cancer was not considered among the inclusion criteria. Many studies had been conducted on NCDs, in particular during the last decade, and the Authors have therefore chosen to use an umbrella methodology for systematic reviews and meta-analyses. Unfortunately, available studies, although reported to be of medium-high quality according to AMSTAR score (mean 8.07 out of 11, ranging from 5 to 11), were based on primary studies of debatable quality, with a large proportion of them lacking discrimination and calibration assessments. Due to the significant heterogeneity of study designs, the risk models involved and the outcomes reported, it was not possible to conduct a meta-analysis. The results were therefore reported narratively. Our electronic search was limited to studies in English and to three major international databases (MEDLINE/PubMed, Scopus and Cochrane Library), with additional works derived from the reference list of studies, and did not include grey literature with unpublished documents. However, a 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 publication bias was estimated by the quantification of ongoing and non-completed systematic reviews in the PROSPERO database. No assessment of potential adverse effects of RPMs has been carried out, with a potential risk of bias.
General interpretation of results
The increasing global growth in prevalence of chronic diseases, as a direct consequence of epidemiologic transition, has led to broader use of predictive tools as a major aid for health workers. Indeed, these instruments can be very important and should be regularly implemented in medical settings to support the activity of general practitioners and public health authorities involved in monitoring and evaluation of patients. Specific benefits of RPMs could emerge in prevention and health promotion for specific populations -such as workers and students-and social settings. It must be pointed out that the studies evaluated in this systematic review, albeit of medium-high quality, are not primary studies and, therefore could be affected by significant bias. Furthermore, there is no evidence in the scientific literature for the evaluation of the effectiveness of RPMs on long-term patient outcomes (35) . Therefore, the results from this study should be carefully applied by health workers, in order to minimize the risk of over-or under-treatment. (36) . Scientific literature in the past 30 years has produced an abundance of evidence on other powerful health determinants, such as social relationships networks, stress, unemployment, education and income (37) (38) (39) (40) , however none of these variables have been included in all the available predictive tools. Moreover, very few instruments considered lifestyle variables like smoking, alcohol, physical activity, and drug use or addiction. A strictly biological perspective should be considered as a serious limitation in terms of forecasting and predicting the development of CVDs, CHDs, diabetes and hypertension. A new generation of predictive tools, conceptually developed around biological and non-biological determinants, could consistently ameliorate the assessment of risk and the detection of risk stratification groups.
Conclusions and future perspectives
The wide range of available studies that have tested risk prediction models for CVDs, CHDs, hypertension and diabetes compare almost overlapping tools (which often differ by only a single entry), does not really increase our knowledge of the issue; rather it merely increases uncertainty. More precise evidence is available only for cardiovascular disease prediction: the Framingham score, alone or in combination with the ankle-brachial index, and QRISK score can be confirmed as the gold standard. Further efforts should not be concentrated on creating new scores, but rather on performing external validation of the existing ones. Promising future possibilities could then involve testing risk scores on wider samples and on certain target populations, such as workers, with specific exposure risks and for which no robust scientific evidence is currently available. These individuals could definitely benefit from early detection of chronic disease, since the conditions are often worsened by occupational exposure and result in disability and absence from work. Benefits could be further improved by supplementing existing models with information on lifestyle, personal habits and family history (23), social network relationships, income, education and employment history.
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